BNP Paribas Financial Markets’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-56,365
| Closed | -$5.75M | – | 4071 |
|
|
2023
Q2 | $5.75M | Buy |
56,365
+22,601
| +67% | +$2.14M | 0.01% | 1164 |
|
|
2023
Q1 | $3.07M | Buy |
33,764
+4,481
| +15% | +$263K | ﹤0.01% | 1545 |
|
|
2022
Q4 | $1.11M | Sell |
29,283
-32,367
| -53% | -$1.11M | ﹤0.01% | 2102 |
|
|
2022
Q3 | $1.55M | Sell |
61,650
-20,322
| -25% | -$563K | ﹤0.01% | 2154 |
|
|
2022
Q2 | $2.49M | Buy |
81,972
+24,938
| +44% | +$744K | ﹤0.01% | 1626 |
|
|
2022
Q1 | $1.87M | Buy |
57,034
+22,592
| +66% | +$670K | ﹤0.01% | 1867 |
|
|
2021
Q4 | $908K | Buy |
34,442
+12,483
| +57% | +$966K | ﹤0.01% | 2654 |
|
|
2021
Q3 | $2.21M | Buy |
21,959
+15,989
| +268% | +$1.87M | ﹤0.01% | 1832 |
|
|
2021
Q2 | $845K | Buy |
5,970
+4,841
| +429% | +$547K | ﹤0.01% | 2278 |
|
|
2021
Q1 | $113K | Buy |
1,129
+328
| +41% | +$38.3K | ﹤0.01% | 3301 |
|
|
2020
Q4 | $99K | Buy |
801
+321
| +67% | +$42.2K | ﹤0.01% | 3214 |
|
|
2020
Q3 | $46.8K | Sell |
480
-6,393
| -93% | -$799K | ﹤0.01% | 3492 |
|
|
2020
Q2 | $1.07M | Sell |
6,873
-639
| -9% | -$97.1K | ﹤0.01% | 1778 |
|
|
2020
Q1 | $1.08M | Buy |
7,512
+4,340
| +137% | +$838K | ﹤0.01% | 1859 |
|
|
2019
Q4 | $648K | Sell |
3,172
-510
| -14% | -$93K | ﹤0.01% | 2282 |
|
|
2019
Q3 | $296K | Buy |
3,682
+1,121
| +44% | +$95.1K | ﹤0.01% | 2524 |
|
|
2019
Q2 | $242K | Sell |
2,561
-1,824
| -42% | -$157K | ﹤0.01% | 2495 |
|
|
2019
Q1 | $375K | Buy |
4,385
+4,207
| +2,363% | +$349K | ﹤0.01% | 2290 |
|
|
2018
Q4 | $9.99K | Sell |
178
-589
| -77% | -$36K | ﹤0.01% | 3353 |
|
|
2018
Q3 | $62.7K | Buy |
767
+184
| +32% | +$13K | ﹤0.01% | 2957 |
|
|
2018
Q2 | $20.4K | Sell |
583
-1,873
| -76% | -$57K | ﹤0.01% | 3491 |
|
|
2018
Q1 | $50.4K | Buy |
2,456
+44
| +2% | +$1.13K | ﹤0.01% | 3562 |
|
|
2017
Q4 | $68.3K | Buy |
2,412
+1,559
| +183% | +$43.5K | ﹤0.01% | 3505 |
|
|
2017
Q3 | $26.5K | Sell |
853
-72
| -8% | -$2.17K | ﹤0.01% | 3449 |
|
|
2017
Q2 | $29.3K | Buy |
925
+840
| +988% | +$20.7K | ﹤0.01% | 3452 |
|
|
2017
Q1 | $1.93K | Sell |
85
-190
| -69% | -$4.69K | ﹤0.01% | 3548 |
|
|
2016
Q4 | $6K | Sell |
275
-120
| -30% | -$3.04K | ﹤0.01% | 3637 |
|
|
2016
Q3 | $10.4K | Buy |
395
+170
| +76% | +$3.37K | ﹤0.01% | 3157 |
|
|
2016
Q2 | $4.44K | Buy |
+225
| New | +$4.37K | ﹤0.01% | 3312 |
|
Other funds holding RETA
BNP Paribas Financial Markets's RETA Position: Q3 2023 in Review
BNP Paribas Financial Markets sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 56,365 shares — an estimated $5.75M sold.
BNP Paribas Financial Markets first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $5.75M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- BNP Paribas Financial Markets reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- BNP Paribas Financial Markets sold 56,365 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $5.75M.
- BNP Paribas Financial Markets first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- BNP Paribas Financial Markets's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.75M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2023, filed 14 Nov 2023.